“First-Line Flumatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: A 3-Month Landmark-Evaluable Real-World Experience”. Mediterranean Journal of Hematology and Infectious Diseases, vol. 18, no. 1, Sept. 2026, p. e2026066, https://doi.org/10.4084/MJHID.2026.066.